Chuan Lian Zi (Sichuan Pagoda Tree Fruit)

Chinese Herb Actions

Chinese Herb Dosage

• What is the typical dosage of Chuan Lian Zi?

  Roughly 3–10 g in decoction, consistent across standard materia medica references. Because the crude herb is bitter, cold, and slightly toxic, it is conventionally processed (dry-fried, chao) before use.

  • Dry-frying (chao) — traditionally said to reduce toxicity, make the herb easier on digestion, and moderate its cold nature.
  • Salt-frying — traditionally said to direct the herb's action toward the Kidney, and is favored specifically for hernial-type pain.

  Modern toxicology context (below) confirms toosendanin — the main active/toxic constituent — as hepatotoxic, and processing measurably reduces its liver-cell toxicity in laboratory models, consistent with this traditional processing practice. This is reference information, not a dosing instruction; dosing and processing choice are a licensed practitioner's decision.

  Source: Sacred Lotus sources & references; cross-referenced against multiple online sources and materia medica consensus (Bensky, Chen & Chen); processing-detoxification research below.

Chinese Herb Contraindications & Cautions

• Are there cautions for Chuan Lian Zi?

  Chuan Lian Zi is classed as “slightly toxic” in the materia medica and is cold in nature, so it is used cautiously in patients with Middle Jiao (Spleen/Stomach) cold-deficiency — its bitter-cold quality can further injure a weak, cold digestion. Standard practice is to use it processed (dry-fried or salt-fried) rather than raw, and within conventional dose ranges, under professional supervision.

  • Use cautiously in patients with cold-deficiency of the Middle Jiao (digestive cold/weakness).
  • Toxicity classification — listed as slightly toxic; conventionally used processed and within standard dose ranges rather than as a raw, high-dose crude herb.

  Source: Sacred Lotus sources & references; cross-referenced against multiple online sources and materia medica consensus (Bensky, Chen & Chen); toxicology research below. Reference note, not administration guidance.

Chinese Herb Toxicity & Overdose

• Documented and real — Melia toosendan is classed as slightly toxic in the materia medica, and modern research confirms its main active compound, toosendanin, is hepatotoxic (liver-damaging) in laboratory and animal models. Multiple recent mechanistic studies (2016–2026) show toosendanin injures liver cells through several overlapping pathways — oxidative stress and reactive-oxygen-species generation, blocked autophagy/lysosomal function, disrupted lipid metabolism, and ferroptosis (iron-dependent cell death) — in hepatocyte cell lines (HepG2, L02), zebrafish, and mouse models. Traditional processing (dry-frying) measurably reduces this hepatotoxicity in these models, echoing the classical practice of never using the crude herb raw.

  Source: materia medica consensus (“slightly toxic” classification); toosendanin hepatotoxicity research (below). Neutral safety reference, not a treatment guide — use of this herb is a licensed-practitioner decision.

• This herb is considered slightly toxic.
  (while some Chinese herbs are toxic, it must be noted that many come prepared, or are combined, to mitigate their toxicity)

Herb-Drug Interactions

• No well-established clinical herb–drug interaction list exists for Chuan Lian Zi, but given its documented hepatotoxic potential, concurrent use with other hepatotoxic substances (including some medications and alcohol) or in patients with pre-existing liver disease warrants professional caution and monitoring. This is a precautionary safety note grounded in the toxicology literature (below), not a demonstrated drug-specific interaction.

Western / Biomedical Research

Chinese Herb Clinical Studies & Research

Provided as research context — a summary of published biomedical study, not a therapeutic or medical claim.

• Is there modern research on Chuan Lian Zi (Fructus Meliae Toosendan) toxicity and use?

  Yes — an active and fairly large modern toxicology literature, concentrated on explaining and reducing the herb's hepatotoxicity, alongside pharmacokinetic research on its classical pairing with Yan Hu Suo. The toxic constituent, toosendanin (a triterpenoid), has been studied across cell, zebrafish, and rodent models published from 2008 through 2026.

  • Hepatotoxicity mechanisms (multiple independent studies) — toosendanin has been shown to injure liver cells via reactive-oxygen-species/MAP-kinase pathways, disrupted autophagy and lysosomal function (including via the STAT3/CTSC axis and TFEB-mediated lysosomal dysfunction), disrupted lipid metabolism (LXRα/Lipin1/SREBP1 pathway), and ferroptosis (PERK-eIF2α-ATF4 signaling and ALOX5-mediated lipid peroxidation) — a convergent, multi-pathway picture of liver injury across independent laboratories and years.
  • Processing/detoxification (network toxicology + experimental verification, 2026) — a study combining network toxicology, molecular docking, and cell experiments identified melianone, toosendanin, and isotoosendanin as the principal hepatotoxic components and confirmed that traditional processing of the crude fruit reduces hepatotoxic effects in liver cell lines, supporting the classical dry-frying practice.
  • Jin Ling Zi San, studied as a formula — a pharmacokinetic study in rats found that combining Fructus Meliae Toosendan with Rhizoma Corydalis (Yan Hu Suo) as Jin Ling Zi San measurably changed the absorption/elimination of both toosendanin and the corydalis alkaloids compared with either herb alone, evidence of a real pharmacokinetic interaction between the pair (not a safety or efficacy claim). A separate 2025 study specifically profiled hepatotoxic constituents within the Jin Ling Zi San formula context.
  • Traditional-use-adjacent pharmacology — animal research has examined Jin Ling Zi San extract components against acetic-acid-induced gastric ulcer, consistent with (but not proof of) its traditional qi-regulating, pain-relieving use.

  Overall, the research base strongly corroborates the traditional “slightly toxic” classification and the value of processing; efficacy research is comparatively preliminary (animal models, formula-level pharmacokinetics) rather than controlled human trials.

  Sources: PMID 38460807 (Chin J Nat Med 2024, DOI 10.1016/S1875-5364(24)60693-X); PMID 38570025 / PMC 12300629 (Pharmaceuticals 2025, DOI 10.3390/ph18071078); PMID 40732365 (Toxicon 2026, DOI 10.1016/j.toxicon.2025.108933); PMID 36801351 (Toxicol Lett 2023, DOI 10.1016/j.toxlet.2023.02.006); PMID 40049104 (Phytomedicine 2025, DOI 10.1016/j.phymed.2025.156586); PMID 33765511 (J Pharm Biomed Anal 2021, DOI 10.1016/j.jpba.2021.114014 — Jin Ling Zi San pharmacokinetics); PMID 30719066 / PMC 6335817 (Evid Based Complement Alternat Med 2019, DOI 10.1155/2019/7365841 — gastric ulcer model); PMID 40520208 / PMC 12162926 (Front Pharmacol 2025, DOI 10.3389/fphar.2025.1585186 — Jin Ling Zi San hepatotoxic constituents). Research context, not a therapeutic or safety claim.

Chinese Herb Notes

• What is Chuan Lian Zi combined with, and how does processing change it?

  Its signature combination is with Yan Hu Suo in equal parts as Jin Ling Zi San, a small, classical two-herb formula for Liver-qi-stagnation-with-heat pain (rib-side, abdominal, or hernial pain with a heat component); Chuan Lian Zi's alternate/historical name, Jin Ling Zi, is the formula's namesake.

  • With Yan Hu Suo (Jin Ling Zi San) — Chuan Lian Zi drains Liver heat and moves qi; Yan Hu Suo moves blood and is a strong analgesic; together they address qi-and-blood stagnation with heat.
  • Dry-fried — lowers toxicity, eases digestibility, tempers the cold property; the general-purpose processed form.
  • Salt-fried — increases affinity for the Kidney channel; traditionally preferred for hernial pain.

  Source: Sacred Lotus sources & references; cross-referenced against multiple online sources and materia medica consensus (Bensky, Chen & Chen); Sacred Lotus formula records for Jin Ling Zi San.

This herb is considered toxic